MK-5108 (VX-689)

Catalog No.S2770

For research use only.

MK-5108 (VX-689) is a highly selective Aurora A inhibitor with IC50 of 0.064 nM in a cell-free assay and is 220- and 190-fold more selective for Aurora A than Aurora B/C, while it inhibits TrkA with less than 100-fold selectivity. MK-5108 (VX-689) induces autophagy. Phase 1.

MK-5108 (VX-689) Chemical Structure

CAS No. 1010085-13-8

Selleck's MK-5108 (VX-689) has been cited by 36 publications

Purity & Quality Control

Choose Selective Aurora Kinase Inhibitors

Other Aurora Kinase Products

Biological Activity

Description MK-5108 (VX-689) is a highly selective Aurora A inhibitor with IC50 of 0.064 nM in a cell-free assay and is 220- and 190-fold more selective for Aurora A than Aurora B/C, while it inhibits TrkA with less than 100-fold selectivity. MK-5108 (VX-689) induces autophagy. Phase 1.
Targets
Aurora A [1]
(Cell-free assay)
0.064 nM
In vitro

MK-5108 inhibits Aurora-A activity in an ATP-competitive manner. MK-5108 shows robust selectivity against the other family kinases Aurora-B (220-fold) and Aurora-C (190-fold) in the biochemical assay. MK-5108 also reveals high selectivity for Aurora-A over other protein kinases. MK-5108 inhibits only one kinase (TrkA) with <100-fold selectivity. MK-5108 may be more Aurora-A selective than MLN8054. Consistent with the induction of pHH3-positive cells, MK-5108 induces accumulation of cells in the G2-M phase. MK-5108 inhibits the proliferation of tumor cells including HCC1143, AU565, MCF-7, HCC1806 and CAL85-1 with an IC50 of 0.42 μM, 0.45 μM, 0.52 μM, 0.56μM and 0.74 μM, respectively. [1] MK-5108 decreases cell viability in a dose-dependent fashion in all three cell lines including LEIO285, LEIO505 and SK-LSM1 cells with an IC50 of approximately 100 nM. Incubation with MK-5108 in LEIO285 increases the proportion of cells in G2/M at 48 and 72 hours post-treatment. MK-5108 significant increases in Caspase 3/7 activity when compared to DMSO-treated control cultures at both time points. In LEIO505 cells, MK-5108 leads to more cells accumulating at G2/M phases at 24 hours but not 48 hours or 72 hours. MK-5108 arrests ULMS cell lines at M phase MK-5108 decreases the IC50 of gemcitabine in LEIO285 cells, but increases IC50 of gemcitabine in LEIO505 and SK-LMS1 cells. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BL21 (DE3) Rosetta MULGeY5kfGmxbjDhd5NigQ>? MUWzNEBucW6| MWHJcohq[mm2aX;uJI9nKEircz30ZYdo\WRiaIXtZY4hSXW{b4LhJGEhc2mwYYPlJEgyOjJidH:gOFAhemW|aXT1[ZMqKGW6cILld5Nm\CCrbjDFd4Np\XKrY3jpZUBkd2yrIFLMNlEhMESHMzmgVo9{\XS2YTDj[YxteyC3c3nu[{BjcW:2aX75cIF1\WRiU2TLNkB{fWK|dILheIUhcW6ldXLheIVlKG[xcjCzNEBucW6|IHL5JGhVWkZiYYPzZZktKEmFNUCgQUAxNjByMEC2OEDPxE1w NUC3RWp{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkezPVEyOzNpPkK3N|kyOTN|PD;hQi=>
HeLa Kyoto MWDGeY5kfGmxbjDhd5NigQ>? MWKyNEBpenN? MnLkTY5pcWKrdHnvckBw\iCDdYLvdoEhSSCtaX7hd4Uh[XW2b4Doc5NxcG:{eXzheIlwdiCjdDDUbJIzQDhiaX6gbJVu[W5iSHXMZUBMgW:2bzDj[YxteyCrbnP1ZoF1\WRiZn;yJFIxKGi{czygTWM2OCB;IECuN{DPxE1w MnnOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd|OUGxN|MoRjJ5M{mxNVM{RC:jPh?=
HCC1143 NIDxZ3NCdnSrcILvcIln\XKjdHnvckBie3OjeR?= NVfscmJjSW62aYDyc4xq\mW{YYTpc44h[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR2MyOTR|IHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4Yh[2WubDDwdo9tcW[ncnH0bY9vNCCLQ{WwJF0hOC52MjFOwG0v M{nmT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUG4NFk3Lz5{OEmxPFA6PjxxYU6=
AU565 M{nGZmFvfGmycn;sbYZmemG2aX;uJIF{e2G7 Mn;GRY51cXC{b3zp[oVz[XSrb36gZYN1cX[rdImgZYdicW6|dDDoeY1idiCDVUW2OUBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHPlcIwheHKxbHnm[ZJifGmxbjygTWM2OCB;IECuOFUh|ryPLh?= NYrLRoh2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5NVgxQTZpPkK4PVE5ODl4PD;hQi=>
MCF7 MWXBcpRqeHKxbHnm[ZJifGmxbjDhd5NigQ>? M1zpRWFvfGmycn;sbYZmemG2aX;uJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHPlcIwheHKxbHnm[ZJifGmxbjygTWM2OCB;IECuOVIh|ryPLh?= M4XCV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUG4NFk3Lz5{OEmxPFA6PjxxYU6=
HCC1806 NFf4PFFCdnSrcILvcIln\XKjdHnvckBie3OjeR?= MVTBcpRqeHKxbHnm[ZJifGmxbjDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFQ{G4NFYh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36sJGlEPTBiPTCwMlU3KM7:TT6= M1e1NVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUG4NFk3Lz5{OEmxPFA6PjxxYU6=
CAL851 NWDaNnBbSW62aYDyc4xq\mW{YYTpc44h[XO|YYm= M2HOUmFvfGmycn;sbYZmemG2aX;uJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQ1HMPFUyKGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gZ4VtdCCycn;sbYZmemG2aX;uMEBKSzVyIE2gNE44PCEQvF2u NIS4R4U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEmxPFA6Pid-Mki5NVgxQTZ:L3G+
HeLa M4PsRmZ2dmO2aX;uJIF{e2G7 M{HHXVE3KG2pL3vn NF7LUHQzKGSjeYO= NVjORlcxWGyjc33hJINwdmOnboTyZZRqd25iaX6gSlM1PC:QIFrjcE1zdnVicnH0JJhmdm:pcnHmeIVlKHerdHigcJVkcW[ncnHz[UBmgHC{ZYPzbY5oKGi3bXHuJGhmVGFiY3XscJMh[XRiMU[gcYcwc2duIIDvJGJKTCCob4KgNkBl[Xm|LDDDdEA:KDFwNzFOwG0v M1myb|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUG4NFk3Lz5{OEmxPFA6PjxxYU6=
HeLa M4nwWmZ2dmO2aX;uJIF{e2G7 Mn;ON|IhdWdxa3e= MYeyJIRigXN? NIPINGVRdGG|bXGgZ49v[2WwdILheIlwdiCrbjDGN|Q1N05iSnPsMZJvfSC{YYSgfIVvd2e{YX\0[YQhf2m2aDDseYNq\mW{YYPlJIV5eHKnc4PpcochcHWvYX6gTIVN[SClZXzsd{BifCB|MjDt[{9s\yxicH:gRmlFKG[xcjCyJIRigXNuIFPwJF0hPC52IN88UU4> MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDlzOEC5Okc,Ojh7MUiwPVY9N2F-
Saos-2 NFn1flJyUFSVIHHzd4F6 NED4[JZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU3Hvd{0zKGOnbHzz MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
MG 63 (6-TG R) M1PKWpFJXFNiYYPzZZk> MUDxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVUdiNkOgLFYuXEdiUjmgZ4VtdHN? M{DJS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
OHS-50 NXfFS5pPeUiWUzDhd5NigQ>? MlzBdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE:KUz21NEBk\Wyucx?= MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SK-N-MC MUjxTHRUKGG|c3H5 MWHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\Wyucx?= M3L3WlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BL21-Codon-Plus(DE3)-RIL M{PRTGZ2dmO2aX;uJIF{e2G7 Mn71NVIxKG2rboO= MWrJcohq[mm2aX;uJI9nKGi3bXHuJG4ufGW{bXnuZYwhUGm|LYTh[4dm\CCDdYLvdoEhSSCneIDy[ZN{\WRiaX6gSZNkcGW{aXPobYEh[2:uaTDCUFIyNUOxZH;uMXBtfXNqRFWzLU1TUUxiY3XscJMhfXOrbnegOU1k[XKkb4j5MYZtfW:{ZYPj[YlvNXlvYX3pco9jfXS7cnnjJIFkcWRvQXzhMWxmfS2DcnetRZJoNUGuYT3T[ZIuVGW3LVfsfU1PUDJiYYOgd5Vje3S{YYTlJIFnfGW{IEGyNEBucW6|IHL5JIZtfW:{ZYPj[Y5k\SCyb3zhdol7[XSrb36gZZMtKEmFNUCgQUAxNjByMEW0JO69VS5? MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNVgzPDR2Lze+R4hGVUKOPD;hQi=>
HeLaS3 NHKyS4NEgXSxdH;4bYNqfHliYYPzZZk> M3ja[VMh\GG7cx?= Mk\TR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVN[VN|IHPlcIx{KGG|c3Xzd4VlKGG|IHPlcIwh\3Kxd4ToJIlvcGmkaYTpc44h[W[2ZYKgN{Bl[Xm|IHL5JHdUXC16IHHzd4F6NCCLQ{WwJF0hOS5{NjFOwG0v M1\yVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMyQDJ2NESvK|5EcEWPQly8M4E,
Assay
Methods Test Index PMID
Western blot p-Aurora A / Aurora-A / N-MYC 29262328
Growth inhibition assay Cell viability 24756365
In vivo MK-5108 induces pHH3-positive cells at doses of 16 mg/kg and 32 mg/kg. Plasma concentration of MK-5108 at 8 mg/kg and 16 mg/kg are 1.7 μM and 4.4 μM, respectively. MK-5108 treatment results in the induction of pHH3 in tumor and skin tissues, which starts at 2 hours and reachs a maximum at 4 hours. MK-5108 treatments at 15 mg/kg and 30 mg/kg results in significant tumor growth inhibition with the change in mean tumor volume for the treatment group as a percentage of the mean change in the control group (%T/C) of 10% and −6% at day 11, and 17% and 5% at day 18, respectively. MK-5108 is well tolerated at both doses, with minimal reduction in body weight. MK-5108 also exhibits significant antitumor activity through intermittent dosing in nude rats bearing SW48 tumors, MK-5108 at 15 mg/kg and 45 mg/kg causes dose-dependent tumor growth inhibition with a %T/C of 35% and 7% at day 10, and 58% and 32% at day 27, respectively. [1]

Protocol (from reference)

Kinase Assay:

[1]

  • Biochemical kinase assays:

    Recombinant His-tagged human Aurora-A protein is expressed in Escherichia coli and is purified with HisTrap HP column. Purified recombinant human Aurora-B and Aurora-C protein are purchased. Experiments are done in quintuplicate in 96-well plates. The Aurora-A assay reaction is conducted in the presence of 20 μM ATP, 25 μM Tetra-Kemptide [RRR(GLRRASLG)4R-NH2], 1.0 μCi per well [γ-33P]-ATP, 0.1 ng per well Aurora-A in 50 mM Tris-HCl (pH 7.4), 15 mM Mg(OAc)2, and 0.2 mM EDTA at 30°C for 40 minutes. To investigate the inhibition mode of MK-5108 for Aurora-A, the IC50 values of MK-5108 are determined in the presence of different concentrations of ATP. Then, the IC50 value is plotted as a function of ATP concentration to analyze the effect of ATP concentration on the IC50 value of MK-5108. The Aurora-B assay reaction is conducted in the presence of 15 μM ATP, 100 μM Kemptide (GLRRASLG-NH2), 1.0 μCi per well [γ-33P]-ATP, 5.0 ng per well Aurora-B in 50 mM Tris-HCl (pH 7.4), 15 mM Mg(OAc)2, and 0.2 mM EDTA at 30 °C for 20 minuts. The Aurora-C assay reaction is conducted in the presence of 40 μM ATP, 100 μM Kemptide, 1.0 μCi per well [γ-33P]-ATP, 15 ng per well Aurora-C in 10 mM MOPS-NaOH (pH 7.4), 5 mM Mg(OAc)2, 1 mM (±) DTT, and 1 mM EGTA at 30 °C for 20 minutes. After kinase reactions are terminated by adding 2.0% phosphoric acid, Tetra-Kemptide or Kemptide is trapped on the MultiScreen-PH plate. Wells are washed five times with 0.64% phosphoric acid and then monitored for radioactivity in a liquid scintillation counter.

Cell Research:

[1]

  • Cell lines: HeLa-S3 cells
  • Concentrations: 0 μM -1 μM
  • Incubation Time: 12 hours
  • Method:

    HeLa-S3 cells are synchronized at the G1-S phase boundary by double thymidine block with 2 mM thymidine. Cells are washed and seeded to 96-well cell culture plates. After 4 hours, an equal volume of medium containing MK-5108 is added to each well. Nocodazole (300 nM) is used as a 100% control. The cells are fixed overnight with cold methanol 12 hours after seeding. Then, the cells are stained with rabbit anti-phospho-histone H3 Ser28 antibody and then with anti-rabbit IgG-Cy5. Total nuclei are stained with 10 mg/mL 4,6-diamidino-2-phenylindole. Immunostained images are acquired using the IN Cell Analyzer1000 with ×10 objective lens. After acquisition of images, data are analyzed. The %pHH3-positive index is determined by measuring the %pHH3-positive cell counts per total nuclei counts for each sample, then by normalizing with respect to nocodazole-treated cells.

Animal Research:

[1]

  • Animal Models: SCID mice bearing HCT116 tumors
  • Dosages: 30 mg/kg
  • Administration: Oral administration

Solubility (25°C)

In vitro

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
0.5% methylcellulose+0.2% Tween 80
For best results, use promptly after mixing.

30 mg/mL

Chemical Information

Molecular Weight 461.94
Formula

C22H21ClFN3O3S

CAS No. 1010085-13-8
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C1CC(CCC1OC2=C(C(=CC=C2)Cl)F)(CC3=NC(=CC=C3)NC4=NC=CS4)C(=O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy MK-5108 (VX-689) | MK-5108 (VX-689) supplier | purchase MK-5108 (VX-689) | MK-5108 (VX-689) cost | MK-5108 (VX-689) manufacturer | order MK-5108 (VX-689) | MK-5108 (VX-689) distributor